Abstract: Provided are an apparatus for diagnosing a disease and a method for diagnosing same. The apparatus includes a pump for pumping respiratory gas, a first pre-treatment portion connected to the pump and removing moisture and bad breath in the respiratory gas, and a volatile organic compound detector connected between the first pre-treatment portion and the pump and detecting volatile organic compounds in the respiratory gas.

Abstract: Techniques are provided that involve employing artificial intelligence (AI) to facilitate reducing adverse outcomes associated with healthcare delivery. In one embodiment, a computer implemented method comprises monitoring live feedback received over a course of care of a patient, wherein the live feedback comprises physiological information regarding a physiological state of the patient. The method further comprises employing AI to identify, based on the live feedback information, an event or condition associated with the course of care of the patient that warrants clinical attention or a clinical response. The method further comprises generating a response, based on the identification of the event or condition, that facilitates reducing an adverse outcome of the course of care, wherein the response varies based on a type of the event or condition, and providing the response to a device associated with an entity involved with treating the patient in association with the course of care.

Abstract: Provided is a method for predicting drug efficacy of lung cancer, including providing a biological sample of a subject with lung cancer; analyzing an expression level of Leucine Zipper Down-regulated in Cancer 1; and predicting the drug efficacy based on the expression level of the Leucine Zipper Down-regulated in Cancer 1. Also provided is kit for predicting drug efficacy of lung cancer in a subject in need thereof, including an antibody against Leucine Zipper Down-regulated in Cancer 1 or a Leucine Zipper Down-regulated in Cancer 1-specific primer. Further provided is a method for treating lung cancer, including enhancing expression of Leucine Zipper Down-regulated in Cancer 1 encoded by Ldoc1 gene in a subject in need thereof.

Abstract: “Herein disclosed is an ex vivo method of identifying a state of a tumor margin in a sample. The method comprises operating a system to generate an ultrasound image and a photoacoustic image, wherein the system comprises: a probe configured to deliver a pulsed laser from a laser source to a sample, wherein the laser source is operable to generate the pulsed laser; arrays coupled to the probe, wherein one of the arrays comprises transducing elements arranged thereon which are operable to transmit and collect ultrasound signals, and wherein one of the arrays comprises transducing elements arranged thereon which are operable to collect photoacoustic signals; and a data acquisition module which converts the ultrasound signals and the photoacoustic signals into the ultrasound image and the photoacoustic image, respectively.

Abstract: The present invention relates to: an organ-on-a-chip for mimicking kidney tissue in which renal tubular epithelial cells and renal fibroblasts are co-cultured; a method for manufacturing the organ-on-a-chip; a device for co-culturing three types of cells; and a method for screening for renal fibrosis therapeutic agents by using the organ-on-a-chip. A kidney-on-a-chip according to one embodiment of the present invention has the excellent effects of enabling the time and errors required in screening for renal fibrosis therapeutic agents to be minimized and renal fibrosis therapeutic agents to be more conveniently and simply screened for through an objective evaluation index.

Abstract: A blood physiological parameter sensing device includes a housing, a flow channel structure, a control unit and a sensing unit. The flow channel structure is disposed in the housing and forms a channel for a liquid to be measured to pass. The control unit is disposed in the housing. The sensing unit is disposed in the housing, is electrically connected to the control unit, and has a sensing end. The sensing end passes through the flow channel structure, is configured in the channel, and has an electrochemical sensing material. The electrochemical sensing material is used to exchange electrons with the blood physiological parameter in the liquid to be measured to produce redox reactions to generate current or voltage change parameters. The sensing unit transmits the current or voltage change parameters to the control unit, which obtains a blood physiological parameter concentration value to achieve instantaneous and continuous monitor the patients.

Abstract: A BAG6 specific chimeric antigen receptor, a nucleic acid, a BAG6 specific chimeric antigen receptor expression plasmid, a BAG6 specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the BAG6 specific chimeric antigen receptor expressing cell are provided. The BAG6 specific chimeric antigen receptor specifically binds to BCL2 associated athanogene 6 (BAG6). The nucleic acid encodes the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expression plasmid expresses the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expressing cell is obtained by transducing the BAG6 specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the BAG6 specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: Disclosed is a method for forming an orthopaedic implant. The method comprises determining one or more parameters of a bone, of a subject, to which the implant is to be attached, and calculating specifications based on parameters. That calculation includes calculating a mechanical property relating to elasticity of the implant, a length of the implant, and positions of two or more fixation locations by which to fix the implant to the bone. The method further comprises forming the implant based on the specifications, wherein each fixation location comprises a longitudinal axis through the implant, and calculating specifications comprises calculating a trajectory for the longitudinal axis of the respective fixation location.

Abstract: Disclosed herein is a method for determining whether a subject is suffering from, or is at risk of developing breast cancer, wherein the method comprises detecting differential expression levels of at least two or more miRNA markers from a biological sample. Also disclosed herein is a method of determining whether a subject is suffering from, or is at risk of developing, breast cancer based on miRNA expression.

Abstract: Embodiments relate to a system and method for electrocardiogram image-based patient evaluation, wherein: a source electrocardiogram image of a target patient is acquired by a user terminal; a server is requested by the user terminal to evaluate the target patient, the request including the source electrocardiogram image; electrocardiogram image-based evaluation information of the patient is generated by the server, the evaluation information of the target patient is transmitted to the user terminal; and reported feedback based on the evaluation information of the target patient is provided by the user terminal.

Abstract: The present invention relates to isolated and engineered human antibodies that specifically bind to at least one conformational (non-linear) epitope of HBsAg and neutralize hepatitis B virus infection, methods for producing the same, and uses thereof in treating human HBV infection.

Abstract: The disclosure provides an eye state assessment method and an electronic device. The method includes: obtaining an optic disc image area from a first fundus photography and generating multiple optic cup-to-disc ratio assessment results by multiple first models based on the optic disc image area; obtaining a first assessment result of an eye based on the optic cup-to-disc ratio assessment results; performing multiple data augmentation operations on the first fundus photography to generate multiple second fundus photographies; generating multiple retinal nerve fiber layer (RNFL) defect assessment results by multiple second models based on the second fundus photographies; obtaining a second assessment result of the eye based on the RNFL defect assessment results; and obtaining an optic nerve assessment result of the eye based on the first assessment result and the second assessment result.

Abstract: An anti-fibrosis pharmaceutical composition and application thereof. The anti-fibrosis pharmaceutical composition specifically comprises: (a) an NRP1 inhibitor and/or an HIF2? inhibitor; and (b) an EPCR pathway activator that promotes the activity of an EPCR pathway. The anti-fibrosis pharmaceutical composition helps reduce organ fibrosis to a certain extent and promotes corresponding organ repair and regeneration.

Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.

Abstract: A peptide mixture suitable for eliciting an immune response, comprising a first peptide and a second peptide. The first peptide comprises a first sequence of at least (8) amino acids, wherein said first sequence has at least 75% sequence identity to a first region of (8) amino acids of SEQ ID NO: 11. This first region includes position (201) of the SEQ ID NO: 11 such that the first sequence includes the amino acid in position (201) of the SEQ ID NO: 11. The second peptide comprises a second sequence of at least (8) amino acids, wherein said second sequence has at least 75% sequence identity to a second region of (8) amino acids of SEQ ID NO: 12. This second region includes position (201) of the SEQ ID NO: 12 such that the second sequence includes the amino acid in position (201) of the SEQ ID NO: 12.

Abstract: The present invention relates to a contact lens-type dressing manufactured by using a partially cured amniotic membrane dressing and a method of manufacturing same. The method of manufacturing a partially cured contact lens-type amniotic membrane dressing, and the partially cured contact lens-type amniotic membrane dressing of the present invention have a simple manufacturing method, can produce a contact lens-type amniotic membrane without foreign matter, have excellent biocompatibility, have excellent lens compatibility such as transparency and tensile strength compared to a fully cured contact lens-type amniotic membrane dressing, and also have excellent wound healing effects, and therefore, can be effectively used for the treatment of eye diseases such as corneal damage.

Abstract: A method is provided, which comprises providing a dried body fluid card sample, extracting body fluid from said dried body fluid card sample, and detecting gene products associated with extracellular vesicles. An application of the method is also applied for diagnosing and/or prognosing a clinical condition, where gene products associated with a population of extracellular vesicles and gene products associated with the clinical condition are detected.

Abstract: In one aspect, disclosed herein is a method of diagnosing and/or prognosing a neurodegenerative disease in a subject, the method comprising: obtaining a plasma or blood sample from a subject; and detecting a level of acetylated Tau in the plasma or blood sample, wherein a level of acetylated Tau that is at least 25% or 50% higher than a control level in a healthy subject indicates that the subject has a neurodegenerative disease such as traumatic brain injury.